These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20154655)

  • 1. A novel antihypertensive effect of exenatide, a GLP-1 agonist.
    Dandona P; Chaudhuri A; Dhindsa S
    Am J Hypertens; 2010 Mar; 23(3):228. PubMed ID: 20154655
    [No Abstract]   [Full Text] [Related]  

  • 2. [Exenatide: use in humans].
    Sierra-Ascencio ME; Ríos-Vaca A; Reza-Albarrán A
    Gac Med Mex; 2006; 142(6):483-91. PubMed ID: 17201111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
    Okerson T; Yan P; Stonehouse A; Brodows R
    Am J Hypertens; 2010 Mar; 23(3):334-9. PubMed ID: 20019672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [GLP-1 agonists: an overview].
    Hinneburg I
    Med Monatsschr Pharm; 2013 Jul; 36(7):246-51. PubMed ID: 23898602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.
    Gallwitz B
    Drug Saf; 2010 Feb; 33(2):87-100. PubMed ID: 20082536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide and weight loss.
    Bradley DP; Kulstad R; Schoeller DA
    Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators.
    Chaudhuri A; Ghanim H; Makdissi A; Green K; Abuaysheh S; Batra M; D Kuhadiya N; Dandona P
    Diabetes Obes Metab; 2017 May; 19(5):729-733. PubMed ID: 27891769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role and indication of GLP-1 analogues in the treatment of type 2 diabetes].
    Philippe J
    Rev Med Suisse; 2009 Jun; 5(206):1260-2, 1264-5. PubMed ID: 19579421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release exenatide (Bydureon) for type 2 diabetes.
    Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
    [No Abstract]   [Full Text] [Related]  

  • 13. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE; Van Gaal LF
    Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].
    Wang XH; Han LN; Yu YR; Wang C; Wang B; Wen XR; Huang H; Jing XC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 46(4):586-90. PubMed ID: 26480664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B
    Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
    Torimoto K; Okada Y; Mori H; Otsuka T; Kawaguchi M; Matsuda M; Kuno F; Sugai K; Sonoda S; Hajime M; Tanaka K; Arao T; Tanaka Y
    Cardiovasc Diabetol; 2015 Feb; 14():25. PubMed ID: 25849903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 19. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
    Bloomgarden ZT
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecule of the month. Exenatide.
    Drug News Perspect; 2003 Nov; 16(9):621. PubMed ID: 14702143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.